[go: up one dir, main page]

MX2017009759A - Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable. - Google Patents

Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable.

Info

Publication number
MX2017009759A
MX2017009759A MX2017009759A MX2017009759A MX2017009759A MX 2017009759 A MX2017009759 A MX 2017009759A MX 2017009759 A MX2017009759 A MX 2017009759A MX 2017009759 A MX2017009759 A MX 2017009759A MX 2017009759 A MX2017009759 A MX 2017009759A
Authority
MX
Mexico
Prior art keywords
vegf
growth factor
vascular endothelial
endothelial growth
antibody formulation
Prior art date
Application number
MX2017009759A
Other languages
English (en)
Inventor
Lee Ingram Rebecca
Elizabeth Weiser Sarah
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55315458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017009759(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MX2017009759A publication Critical patent/MX2017009759A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al campo de las formulaciones farmacéuticas de anticuerpos; en forma específica, la presente invención se refiere a una formulación de anticuerpo líquido estable y su preparación farmacéutica y uso; esta invención se ejemplifica por una formulación acuosa de un anticuerpo anti-factor de crecimiento vascular endotelial (VEGF).
MX2017009759A 2015-01-28 2016-01-20 Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable. MX2017009759A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562108811P 2015-01-28 2015-01-28
US201562265514P 2015-12-10 2015-12-10
PCT/IB2016/050273 WO2016120753A1 (en) 2015-01-28 2016-01-20 Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation

Publications (1)

Publication Number Publication Date
MX2017009759A true MX2017009759A (es) 2017-10-27

Family

ID=55315458

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009759A MX2017009759A (es) 2015-01-28 2016-01-20 Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable.

Country Status (11)

Country Link
US (2) US10894083B2 (es)
EP (1) EP3250596A1 (es)
JP (1) JP6877878B2 (es)
CN (1) CN107206080B (es)
AU (2) AU2016210918A1 (es)
BR (1) BR112017014376A2 (es)
CA (1) CA2918714A1 (es)
CO (1) CO2017007693A2 (es)
MX (1) MX2017009759A (es)
RU (1) RU2699544C2 (es)
WO (1) WO2016120753A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
IL260323B2 (en) 2015-12-30 2025-01-01 Kodiak Sciences Inc Antibodies and their conjugates
KR20200140817A (ko) 2018-03-02 2020-12-16 코디악 사이언시스 인코포레이티드 Il-6 항체 그리고 이의 융합 작제물 및 접합체
WO2019171253A1 (en) * 2018-03-07 2019-09-12 Pfizer Inc. Anti-pd-1 antibody compositions
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
BR112022001017A2 (pt) 2019-07-19 2022-04-12 Sinocelltech Ltd Anticorpo monoclonal anti-vegf humanizado
US20220265825A1 (en) * 2019-08-01 2022-08-25 Gennova Biopharmaceuticals Limited Opthalmic composition of bevacizumab
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
BR112022007635A2 (pt) * 2019-11-13 2022-07-12 Pfizer Formulação aquosa e estável de anticorpos
KR20220001106A (ko) * 2020-06-29 2022-01-05 (주)메디톡스 고농도 항-ｖｅｇｆ 항체 제제 및 이에 사용하기 위한 항-ｖｅｇｆ 항체
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
CN118593699A (zh) * 2023-03-06 2024-09-06 百奥泰生物制药股份有限公司 一种稳定的抗vegf抗体制剂

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US692A (en) 1838-04-14 Improvement in machines for mowing and cutting grass and grain
US377A (en) 1837-09-08 Turnek whitehouse
US297A (en) 1837-07-29 Improvement in fire-arms
US6350A (en) 1849-04-17 Moetising-machine
US6054A (en) 1849-01-23 Improved process for welding cast to wrought iron or steel
US6210A (en) 1849-03-20 chambeelain
US671A (en) 1838-04-04 Improved machine for breaking hemp and flax
US6180A (en) 1849-03-13 Improved furnace for smelting zinc
US867A (en) 1838-08-01 Improved adhesive compound for binding books
US861A (en) 1838-07-28 Improved water-wheel
US5866A (en) 1848-10-17 Dentist s deill
US5997A (en) 1849-01-02 Swinging bridge
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
CN100480269C (zh) 1997-04-07 2009-04-22 基因技术股份有限公司 抗-血管内皮生长因子的抗体
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
DE69810481T2 (de) 1997-06-13 2003-09-25 Genentech Inc., San Francisco Stabilisierte antikörperformulierung
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
PT1324776E (pt) 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
AU2003211991B2 (en) 2002-02-14 2008-08-21 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution formulations
CN1753693A (zh) * 2003-02-13 2006-03-29 辉瑞产品公司 抗－胰岛素样生长因子ⅰ受体抗体的用途
CN1946352A (zh) * 2004-04-09 2007-04-11 狄科特康坦特公司 递送药物至眼以治疗后段疾病的方法和物品
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2995971A1 (en) 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations
MX2008013535A (es) 2006-04-21 2008-10-29 Amgen Inc Agentes amortiguadores para formulaciones biofarmaceuticas.
JP5216002B2 (ja) 2006-06-16 2013-06-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 硝子体内投与に適したｖｅｇｆアンタゴニスト製剤
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
KR20210049186A (ko) 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
ES2793008T3 (es) 2008-06-25 2020-11-12 Novartis Ag Anticuerpos estables y solubles que inhiben VEGF
US9155745B2 (en) 2009-06-16 2015-10-13 Universite De Geneve Bevacizumab formulations with lower aggregation propensity, comprising corticosteroid anti-inflammatory drugs
WO2011028962A1 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody coformulations
ES2765657T3 (es) * 2009-12-21 2020-06-10 Hoffmann La Roche Formulación farmacéutica de bevacizumab
RS61082B1 (sr) 2010-02-26 2020-12-31 Novo Nordisk As Stabilno antitelo koje sadrži kompozicije
JP5937523B2 (ja) 2010-03-01 2016-06-22 サイトダイン インコーポレイテッドＣｙｔｏＤｙｎ， Ｉｎｃ． 濃縮されたタンパク質製剤およびその使用
JP2013523717A (ja) 2010-03-31 2013-06-17 ユニベルシテ ドゥ ジュネーブ 安定化された抗体調製物およびその使用
TR201810930T4 (tr) 2012-05-18 2018-08-27 Genentech Inc Yüksek konsantrasyonlu monoklonal antikor formülasyonları.
KR20150033620A (ko) 2012-06-01 2015-04-01 옵쏘테크 코포레이션 항-pdgf 압타머 및 vegf 길항제를 포함하는 조성물
US20130323242A1 (en) 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
CN104854133B (zh) * 2012-10-12 2018-10-30 新加坡科技研究局 用于制备重组抗体治疗剂的最佳重链和轻链信号肽
JP6511609B2 (ja) 2013-03-13 2019-05-22 ジェネンテック， インコーポレイテッド 抗体製剤
ES2875878T3 (es) 2013-11-18 2021-11-11 Formycon Ag Composición farmacéutica de un anticuerpo anti-VEGF
CN104906576B (zh) 2014-03-13 2018-06-19 四川科伦博泰生物医药股份有限公司 可供皮下注射的高浓度抗vegf抗体配制剂
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
WO2016044334A1 (en) 2014-09-15 2016-03-24 Genentech, Inc. Antibody formulations
TWI761959B (zh) 2014-11-07 2022-04-21 瑞士商諾華公司 治療眼部疾病之方法
WO2016103139A1 (en) 2014-12-22 2016-06-30 Dr. Reddy's Laboratories Method for reduction of aggregates
CN106511997A (zh) 2015-09-15 2017-03-22 上海抗体药物国家工程研究中心有限公司 一种稳定的蛋白制剂
WO2017070460A1 (en) 2015-10-22 2017-04-27 Massachusetts Institute Of Technology Vegf-a-binding proteins and her2-binding proteins with enhanced stability against aggregation

Also Published As

Publication number Publication date
AU2016210918A1 (en) 2017-07-13
US10894083B2 (en) 2021-01-19
JP6877878B2 (ja) 2021-05-26
US20210128729A1 (en) 2021-05-06
US20180000933A1 (en) 2018-01-04
AU2021245230A1 (en) 2021-11-04
CO2017007693A2 (es) 2017-10-10
CN107206080B (zh) 2022-07-08
CN107206080A (zh) 2017-09-26
RU2017123972A3 (es) 2019-03-01
BR112017014376A2 (pt) 2018-05-02
WO2016120753A1 (en) 2016-08-04
RU2699544C2 (ru) 2019-09-06
CA2918714A1 (en) 2016-07-28
RU2017123972A (ru) 2019-03-01
EP3250596A1 (en) 2017-12-06
JP2016138097A (ja) 2016-08-04

Similar Documents

Publication Publication Date Title
MX2017009759A (es) Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable.
MX2017004975A (es) Composiciones de anticuerpos anti-il-7r.
EA201690667A1 (ru) Композиции, содержащие антитело к pdl1
EA201891339A1 (ru) Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
IL280087B (en) Stable formulations of protein solutions containing a high concentration of anti-vegf antibody
MX2020009275A (es) Composiciones de anticuerpo anti-pd-1.
MX2017010400A (es) Formulacion liquida estable para anticuerpos monoclonales.
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CY1120937T1 (el) Φαρμακευτικη μορφοποιηση αντισωματος anti-tnf-αλφα
IL252141A0 (en) Pharmaceutical products and stable liquid compositions of il-17 antibodies
EA201792500A1 (ru) Aav-опосредованная экспрессия антител против гриппа и способы их использования
EA201691945A1 (ru) Антитела к гемагглютинину вируса гриппа типа b и способы их применения
MX381232B (es) Formulación de anticuerpos.
AR098168A1 (es) Formulación estable de insulina glulisina
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
EA201790650A1 (ru) Лекарственная форма и способы применения абиратерона ацетата
EA201992027A1 (ru) Водный состав антитела против pd-l1
EA201400609A1 (ru) Твердые формы препаратов иматиниба, ресуспензируемые непосредственно перед применением
EP3498263A4 (en) STABLE LIQUID PHARMACEUTICAL PREPARATION FOR ANTI-INFLUENZA VIRUS ANTIBODIES
NI201800016A (es) Composición herbicida y proceso para prepararla
EA201892157A1 (ru) Фосфаплатиновые жидкие составы
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
MX2022005836A (es) Formulacion estable de anticuerpos acuosos.
EA201690706A1 (ru) Пенообразующий препарат и устройство для доставки